Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03216460 · ClinicalTrials.gov registry record · NA
Insulet Artificial Pancreas Free-Living IDE3
A NA study, sponsored by Insulet Corporation.
- Completed
- Registry status
- NA
- Development phase
- 120
- Enrollment target
NCT03216460 is a NA study that has completed, run by Insulet Corporation. The registered enrollment target is 120 participants.
The verdict
NCT03216460, a NA study, has completed, sponsored by Insulet Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
Study Summary
Subjects will undergo a 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. Subjects or their caregivers will manage their diabetes at home per their usual routine using the study CGM and remain on current MDI or pump therapy. This will be followed by a 5-day/4-night or from approximately 48 to 72 hours for children ages 2.0-5.9 years, hybrid closed-loop phase conducted in a supervised hotel/rental house setting.
Interventions
- DEVICE Insulet automated glucose control system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-02-04 |
| Est. Completion | 2019-05-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03216460
The ClinicalTrials.gov registry entry for NCT03216460 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insulet Corporation, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Insulet automated glucose control system is the first listed.
NCT03216460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03216460 about?
NCT03216460 is a clinical study titled "Insulet Artificial Pancreas Free-Living IDE3". Subjects will undergo a 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. Subjects or their caregivers will manage their diabetes at home per their usual routine using the study CGM and remain on current MDI or pump therapy. This will be followed by a...
What is the current status of trial NCT03216460?
This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 2019-02-04. Estimated completion is 2019-05-28.
What interventions are being tested in trial NCT03216460?
The interventions under investigation include: Insulet automated glucose control system (DEVICE).
Who is sponsoring clinical trial NCT03216460?
This trial is sponsored by Insulet Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.